[1] Templeton AJ, McNamara MG, eruga B, et al. Prognostic role of neutrophiltolymphocyte ratio in solid tumors: a systematic review and meta analysis[J]. J Natl Cancer Inst, 2014, 106(6): dju124. DOI: 10.1093/jnci/dju124.
[2] Li QQ, Lu ZH, Yang L, et al. Neutrophil count and the inflammationbased glasgow prognostic score predict survival in patients with advanced gastric cancer receiving firstline chemotherapy[J]. Asian Pac J Cancer Prev, 2014, 15(2): 945950.
[3] Lee S, Oh SY, Kim SH, et al. Prognostic signifcance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy[J]. BMC Cancer, 2013, 13: 350. DOI: 10.1186/1471240713350.
[4] Feng JF, Huang Y, Zhao Q, et al. Clinical significance of preoperative neutrophil lymphocyte versus platelet lymphocyte ratio in patients with small cell carcinoma of the esophagous[J]. Sci World J, 2013, 2013: 504365. DOI: 10.1155/2013/504365.
[5] Kishi Y, Kopetz S, Chun YS, et al. Blood neutrophiltolymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy[J]. Ann Surg Oncol, 2009, 16(3): 614622. DOI: 10.1245/s1043400802676.
[6] Mizunuma M, Yokoyama Y, Futagami M, et al. The pretreatment neutrophiltolymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer[J]. Int J Clin Oncol, 2015, 20(5): 989996. DOI: 10.1007/s1014701508076.
[7] Shaverdian N, Veruttipong D, Wang J, et al. Pretreatment immune parameters predict for overall survival and toxicity in earlystage nonsmallcell lung cancer patients treated with stereotactic body radiation therapy[J]. Clin Lung Cancer, 2016, 17(1): 3946. DOI: 10.1016/j.cllc.2015.07.007.
[8] Shimada H, Oohira G, Okazumi S, et al. Thrombocytosis associated with poor prognosis inpatients with esophageal carcinoma[J]. J Am Coll Surg, 2004, 198(5): 737741. DOI: 10.1016/J.jamcollsurg.2004.01.022.
[9] Kwon HC, Kim SH, Oh SY, et al. Clinical significance of preoperative neutrophillymphocyte versus plateletlymphocyte ratio in patients with operable colorectal cancer[J]. Biomarkers, 2012, 17(3): 216222. DOI: 10.3109/1354750X.2012.656705.
[10] Naina HV, Harris S. Paraneoplastic thrombocytosis in ovarian cancer[J]. N Engl J Med, 2012, 366(19): 1840. DOI: 10.1056/NEJMc1203095#SA1.
[11] Sharma D, BrummelZiedins KE, Bouchard BA, et al. Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer[J]. J Cell Physiol, 2014, 229(8): 10051015. DOI: 10.1002/jcp.24539.
[12] Stegner D, Dütting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis[J]. Thromb Res, 2014, 133 Suppl 2: S149S157. DOI: 10.1016/S00493848(14)500254.
[13] Suzuki K, Aiura K, Ueda M, et al. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents[J]. Pancreas, 2004, 29(2): 132140. |